NZ Immuno-Oncology Research Review Issue 35

In this issue:
  -  ctDNA-guided adjuvant atezolizumab in muscle invasive bladder cancer
  -  Immunotherapy prescribing and immune-related adverse events in head and neck cancer
  -  Deep-learning serial CT for predicting survival in ICI-treated NSCLC
  -  Time-of-day immunochemotherapy in NSCLC
  -  Adding FMT to immunotherapy in NSCLC or melanoma
  -  Anti-Claudin18.2×CD3 bispecific antibody for solid tumours, including gastric/ gastro-oesophageal
  -  Real-world neoadjuvant therapy ± pembrolizumab for triple-negative breast cancer
  -  First-line ipilimumab nivolumab in advanced Merkel cell carcinoma
  -  Real-world immunotherapy discontinuation at 2 years in advanced NSCLC
  -  Pembrolizumab for recurrent/ metastatic medullary thyroid cancer

Please login below to download this issue (PDF)

Subscribe